Abstract
New insights into the pathophysiology of chemotherapy-induced nausea and vomiting, a better understanding of patients at risk, and the availability of new antiemetic agents have all contributed to substantial improvements in emetic control. This review focuses on our current understanding of chemotherapy-induced nausea and vomiting and the status of pharmacologic interventions in its prevention and treatment.